{"id":"W2543681710","doi":"10.1182/blood.v118.21.3849.3849","title":"An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Constitutional symptoms; Dosing; Internal medicine; Polycythemia vera; Multicenter study; Phases of clinical research; Gastroenterology; Adverse effect; Anemia; Surgery; Clinical trial; Bone marrow; Disease; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002842296,0.001295019,0.001204504,0.000413974,0.000490619,0.0004410156,0.0007552901,0.0008165066,0.003001479],"category_scores_gemma":[0.0007683057,0.0005065625,0.0004666832,0.0002874887,0.0006008739,0.0006130294,0.0003701222,0.002253813,0.000669651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003877714,"about_ca_system_score_gemma":0.001210227,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005316465,"about_ca_topic_score_gemma":0.001249154,"domain_scores_codex":[0.9994597,0.0003169455,0.00002463888,0.000072325,0.00005480646,0.00007153094],"domain_scores_gemma":[0.9992045,0.0001228273,0.0001021642,0.00007563228,0.0000749072,0.0004200293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5050915,0.1430705,0.01451753,0.0007765444,0.0008833739,0.000827019,0.0005853907,0.002136326,0.1979486,0.0003581329,0.007273185,0.1265318],"study_design_scores_gemma":[0.4235619,0.5322302,0.0278572,0.00003739082,0.0004058347,0.0006444392,0.00006194985,0.001317506,0.009963674,0.0001728023,0.003714307,0.0000326739],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943441,0.0009741445,0.0005872555,0.000263888,0.0000455603,0.002260071,0.0005742735,0.00008083096,0.0008698885],"genre_scores_gemma":[0.9885949,0.0008317585,0.003139127,0.0005967994,0.0001840418,0.002651512,0.002334931,0.00003190801,0.001634931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003001479,"threshold_uncertainty_score":0.01503164,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05319811628048467,"score_gpt":0.3306592091384076,"score_spread":0.277461092857923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}